EUVIMEDEUVIMED entdecken
Crossref

Gene expression profile of immune-check point in response to Trastuzumab therapy in patients with HER-2 positive breast cancer

Noor A Abdullah, Naael Hussein Ali, Nabeel Abdu Aljaleel

Wiadomości Lekarskie · 2024

DOI: 10.36740/wlek202405127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Wiadomości Lekarskie, 2024. Verfasst von Noor A Abdullah und 2 weiteren Autor:innen. Beteiligte Einrichtung: COLLEGE OF MEDICINE, UNIVERSITY OF BASRAH, BASRAH, IRAQ. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To clarify the association between response to Trastuzumab and molecular expression of TIM-3 and FOXP-3 immune checkpoints. Materials and Methods: FOXP-3 and TIM-3 expression in peripheral blood was analyzed using qPCR, and the serum level of Trastuzumab was estimated using an immune sorbent enzyme assay.

Results

During treatment with Trastuzumab, the FOXP-3 gene expression showed a significant decline throughout one year of treatment, going from 0.85 at cycle 9 to 0.75 at cycle 17. While the TIM-3 gene expression showed a significant up regulation at cycle 9 to 2.8 fold, followed by a reduction in the fold change from 2.8 to 1.7 in the font of reference gene expression. Conclusions:FOXP-3 and TIM-3 have the potential to be suggestive markers that can anticipate the response to Trastuzumab, but they are not capable of predicting the likelihood of recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansFemaleHepatitis A Virus Cellular Receptor 2Antineoplastic Agents, ImmunologicalMiddle AgedAdultBiomarkers, TumorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

HER-2Trastuzumabimmune checkpointsFOXP-3breast cancerTIM-3

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesHepatitis A Virus Cellular Receptor 2Antineoplastic Agents, ImmunologicalBiomarkers, TumorERBB2 protein, humanHAVCR2 protein, human

Autor:innen und Institutionen

  • COLLEGE OF MEDICINE, UNIVERSITY OF BASRAH, BASRAH, IRAQ.

Zitieren

APA

Abdullah, N. A., Ali, N. H., & Aljaleel, N. A. (2024). Gene expression profile of immune-check point in response to Trastuzumab therapy in patients with HER-2 positive breast cancer. Wiadomości Lekarskie. https://doi.org/10.36740/wlek202405127

Vancouver

Abdullah NA, Ali NH, Aljaleel NA. Gene expression profile of immune-check point in response to Trastuzumab therapy in patients with HER-2 positive breast cancer. Wiadomości Lekarskie. 2024. doi:10.36740/wlek202405127

BibTeX
@article{Abdullah2024,
  author = {Abdullah, Noor A and Ali, Naael Hussein and Aljaleel, Nabeel Abdu},
  title = {Gene expression profile of immune-check point in response to Trastuzumab therapy in patients with HER-2 positive breast cancer},
  journal = {Wiadomości Lekarskie},
  year = {2024},
  doi = {10.36740/wlek202405127}
}
Kostenlos starten →